Breast cancer family history and contralateral breast cancer risk in young women: An update from the Women’s Environmental Cancer and Radiation Epidemiology study Journal Article


Authors: Reiner, A. S.; Sisti, J.; John, E. M.; Lynch, C. F.; Brooks, J. D.; Mellemkjær, L.; Boice, J. D.; Knight, J. A.; Concannon, P.; Capanu, M.; Tischkowitz, M.; Robson, M.; Liang, X.; Woods, M.; Conti, D. V.; Duggan, D.; Shore, R.; Stram, D. O.; Thomas, D. C.; Malone, K. E.; Bernstein, L.; The WECARE Study Collaborative Group; Bernstein, J. L.
Contributor: Orlow, I.
Article Title: Breast cancer family history and contralateral breast cancer risk in young women: An update from the Women’s Environmental Cancer and Radiation Epidemiology study
Abstract: The Women’s Environmental Cancer and Radiation Epidemiology (WECARE) study demonstrated the importance of breast cancer family history on contralateral breast cancer (CBC) risk, even for noncarriers of deleterious BRCA1/2 mutations. With the completion of WECARE II, updated risk estimates are reported. Additional analyses that exclude women negative for deleterious mutations in ATM, CHEK2*1100delC, and PALB2 were performed. Patients and Methods The WECARE Study is a population-based case-control study that compared 1,521 CBC cases with 2,212 individually matched unilateral breast cancer (UBC) controls. Participants were younger than age 55 years when diagnosed with a first invasive breast cancer between 1985 and 2008. Women were interviewed about breast cancer risk factors, including family history. A subset of women was screened for deleterious mutations in BRCA1/2, ATM, CHEK2*1100delC, and PALB2. Rate ratios (RRs) were estimated using multivariable conditional logistic regression. Cumulative absolute risks (ARs) were estimated by combining RRs from the WECARE Study and population-based SEER*Stat cancer incidence data. Results Women with any first-degree relative with breast cancer had a 10-year AR of 8.1% for CBC (95% CI, 6.7% to 9.8%). Risks also were increased if the relative was diagnosed at an age younger than 40 years (10-year AR, 13.5%; 95% CI, 8.8% to 20.8%) or with CBC (10-year AR, 14.1%; 95% CI, 9.5% to 20.7%). These risks are comparable with those seen in BRCA1/2 deleterious mutation carriers (10-year AR, 18.4%; 95% CI, 16.0% to 21.3%). In the subset of women who tested negative for deleterious mutations in BRCA1/2, ATM, CHEK2*1100delC, and PALB2, estimates were unchanged. Adjustment for known breast cancer single-nucleotide polymorphisms did not affect estimates. Conclusion Breast cancer family history confers a high CBC risk, even after excluding women with deleterious mutations. Clinicians are urged to use detailed family histories to guide treatment and future screening decisions for young women with breast cancer. © 2018 by American Society of Clinical Oncology.
Journal Title: Journal of Clinical Oncology
Volume: 36
Issue: 15
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2018-05-20
Start Page: 1513
End Page: 1520
Language: English
DOI: 10.1200/jco.2017.77.3424
PROVIDER: scopus
PUBMED: 29620998
DOI/URL:
Notes: Article -- Export Date: 1 June 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Anne S Reiner
    115 Reiner
  2. Mark E Robson
    358 Robson
  3. Irene Orlow
    190 Orlow
  4. Marinela Capanu
    189 Capanu
  5. Jonine L Bernstein
    100 Bernstein
  6. Xiaolin Liang
    41 Liang
  7. Julia Shafto Sisti
    4 Sisti
  8. Meghan   Woods
    13 Woods